
Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
pharmafile | October 3, 2018 | News story | Research and Development, Sales and Marketing | Cancer, Eli Lilly, Verzenio, breast cancer, pharma
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.
The therapy has been authorised in the first-line treatment of hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, as well as a second-line treatment after earlier endocrine drugs.
The decision was built upon the findings of two trials exploring Verzenio’s efficacy in both first-line and second-line indications.
This latest approval follows authorisation in the US back in February, when it was approved for first-line use. According to Lilly, the drug generated nearly $58 million in sales in the second quarter of this year, up $20 million from the previous quarter.
The manufacturer has also claimed that Verzenio is outperforming Novartis’ Kisqali in terms of new prescriptions, while Lilly also looks to muscle in on the territory occupied by the market leader, Pfizer’s Ibrance.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of …






